Elegance in Molecular Design

  • Targeted

  • Dual-acting

  • small molecule treatments

Header mobile v4.8.png

Technology built on two Novel platforms:


Anti-angiogenic & Anti-Tubulin

Small water-soluble molecules for highly vascularized tumors. Designed to be dual-acting (Anti-angiogenic and Anti-tubulin) in a single agent. Developed for the treatment of Glioblastoma Multiforme (GBM) and triple-negative breast cancer.

Purine Synthesis inhibitor

Highly potent, water-soluble molecules engineered to selectively bind to cancer cells and inhibit purine synthesis at multiple points. Developed for mesothelioma, ovarian, kidney and pancreatic cancers.


Meet FLAG-003

Our lead Candidate


FLAG Therapeutics is developing a first-in-class, dual-acting small molecule for the treatment of Glioblastoma. FLAG-003 is a water-soluble hybrid-scaffold elegantly designed to target cancer cells. With a unique dual-mechanism of action, FLAG-003 is small enough to pass the blood-brain barrier and is engineered to simultaneously block the formation of new blood vessels and kill cancer cells.

*FLAG-003 is currently under investigational use.

Glioblastoma header 800x600 v2.png

Major Milestones

Awarded $1.5 M 2 year SBIR to study Purine Synthesis Inhibitors for the treatment of Mesothelioma

Pre-IND meeting held with US FDA for FLAG-003

Orphan Drug Designation granted for FLAG-003 for the treatment of Glioma in both the US and EU.


FLAG to Present at World Orphan drug Congress (Apr. 13)

February 17, 2019

FLAG Issued 2 new patents

January 29, 2019

Header v5.1.png



Interested in FLAG's technology? Please send us a message and we'll be in touch.